Pacer Advisors Inc. Has $22.27 Million Stock Holdings in Medpace Holdings, Inc. $MEDP

Pacer Advisors Inc. decreased its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 69.8% in the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 46,381 shares of the company’s stock after selling 107,271 shares during the period. Pacer Advisors Inc.’s holdings in Medpace were worth $22,272,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Steigerwald Gordon & Koch Inc. acquired a new position in Medpace in the fourth quarter valued at about $30,000. Elyxium Wealth LLC bought a new stake in shares of Medpace in the 4th quarter valued at about $30,000. Quarry LP acquired a new stake in shares of Medpace in the 3rd quarter valued at approximately $35,000. Bayban bought a new position in Medpace during the 4th quarter worth approximately $44,000. Finally, Core Wealth Advisors LLC bought a new position in Medpace during the 4th quarter worth approximately $47,000. 77.98% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on MEDP shares. Leerink Partners set a $620.00 price objective on shares of Medpace in a report on Thursday, July 23rd. Mizuho increased their target price on shares of Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a report on Friday, July 24th. TD Cowen lifted their price target on shares of Medpace from $419.00 to $492.00 and gave the stock a “hold” rating in a research report on Friday, July 24th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $535.00 price target on shares of Medpace in a report on Thursday, July 23rd. Finally, Truist Financial upped their price objective on shares of Medpace from $462.00 to $609.00 and gave the company a “hold” rating in a research report on Friday, July 24th. Two research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the stock. Based on data from MarketBeat.com, Medpace presently has a consensus rating of “Hold” and an average price target of $584.18.

Medpace Price Performance

NASDAQ:MEDP opened at $573.29 on Tuesday. Medpace Holdings, Inc. has a fifty-two week low of $373.00 and a fifty-two week high of $677.90. The stock has a market capitalization of $16.00 billion, a PE ratio of 33.60, a price-to-earnings-growth ratio of 2.57 and a beta of 1.15. The business’s 50-day simple moving average is $510.42 and its 200-day simple moving average is $492.78.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The business had revenue of $707.33 million during the quarter, compared to analyst estimates of $689.51 million. During the same period in the previous year, the firm earned $3.10 EPS. Medpace’s quarterly revenue was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, research analysts expect that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year.

Insider Buying and Selling at Medpace

In related news, General Counsel Stephen P. Ewald sold 16,349 shares of the firm’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the sale, the general counsel directly owned 20,343 shares in the company, valued at $9,154,350. This trade represents a 44.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Susan E. Burwig sold 7,500 shares of the firm’s stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $600.00, for a total transaction of $4,500,000.00. Following the sale, the vice president owned 62,984 shares in the company, valued at approximately $37,790,400. The trade was a 10.64% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 31,087 shares of company stock valued at $16,203,054. 20.50% of the stock is currently owned by corporate insiders.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.